comparemela.com
  1. Home
  2. Live Updates
  3. Anti Cd19 - Breaking News

Latest Breaking News On - Anti cd19 - Page 1 : comparemela.com

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz nowakowskiFive year efficacyPatients with relapsedFinal results fromPartnership withDiffuse largeb cell lymphomaB cell lymphomaL mind trialL mind studyTl mindAnti cd19

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.